Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Destiny Pharma Plc LSE:DEST London Ordinary Share GB00BDHSP575 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  11.00 6.92% 170.00 168.00 171.00 170.50 159.00 159.00 93,547 16:35:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -5.5 -10.7 - 102

Destiny Pharma Share Discussion Threads

Showing 501 to 524 of 525 messages
Chat Pages: 21  20  19  18  17  16  15  14  13  12  11  10  Older
DateSubjectAuthorDiscuss
09/4/2021
09:01
This latest dip in the share price is a great opportunity for new investors to get on board as well as PIs like myself to top up my current holding. An extract from the latest House broker's note suggests there is still massive potential upside. 'Whilst the shares have more than doubled year-to-date, we see further substantial upside. As a consequence of this data, we raise our risk-adjusted NPV target price to 370p, on account of increasing the probability of XF-73 reaching the market from 53% to 67%. This excludes any value for other XF platform drugs or SPOR-COV, which may enter the clinic in 2022.'
sev22
08/4/2021
11:41
Also dip will be due to the many who have had a generally excellent "gains" in tax year 2020/21 and if not ISA'd are well up to their CGT tax-free £12,300 limits for that year. Likely many DEST holders will have held off selling any of their huge DEST gains until slicing some off in the new 2021/2022 tax year. Need to remember that Dec 2020 buyers bought in the 60p's! f
fillipe
07/4/2021
19:10
MW, I think the disappointing share price is unrelated to the potential opportunity here, it's more down to AIM. The more illiquid the stock, the more it can be manipulated by MMs and used by traders for short term profits - both acting against interests of long term investors. But I think you are right, the market is probably thinking there may be discounted fundraising to fund the 2 phase 3 trials. I think the company is partly to blame for being sooooo vague about their commercial plans when the trial results were announced . They could have been much clearer about this, without mentioning names of potential partners and without breaking confidentiality. Perhaps when annual results are announced next week they will give more information (but I'm not holding my breath). Personally I'm not too fussed, just a little frustrated ; I am supremely confident this will multibag from here because of the massive commercial potential of XF-73 alone, especially as it has been largely derisked with the IIb results. It is just a matter of when.
kipper1960
07/4/2021
16:38
reaction to the phase 2 results a bit of a damp squib...is it accepted generally that nasal carriers of staph aureus suffer a 10x risk of postop wound infection? is their formulation sufficiently advantageous over simple elimination of nasal carriage by eg preop or introperative local iodine/alcohol applications, though I imagine these might be rejected on grounds of safety/irritation. Market must be frightened of the prospect of having to pay for the costly phase 3 studies.
mw8156
06/4/2021
17:39
https://ukinvestormagazine.co.uk/destiny-pharma-set-for-next-phase/
sev22
31/3/2021
15:39
For anyone who missed it live, here's the video of CEO & CFO explaining the excellent study results just received, and then answering multiple private investor questions : https://www.equitydevelopment.co.uk/research/webinar-recording-on-phase-2b-study-results
edmonda
30/3/2021
17:58
He talked about Phase 3 from H2 2022 if I recall right. Long wait for results that will probably be just as conclusive as P2b (hopefully). This is a share for the coffee can - put it in and forget about it.
gaiusgracchus
30/3/2021
16:23
Straightforward presentation. With no competitor product available with clinical grade data (never mind 99.5% efficacy) the market appears open to DEST. There should be partners aplenty and further grant funding. Concern about large-scale fundraise for P3 would therefore seem to be overdone.
t0pgrader
29/3/2021
12:34
New placing a commeth
richardp19
29/3/2021
12:08
https://twitter.com/doit4thetwins/status/1376484750706237444?s=21
mikeh30
29/3/2021
12:08
AMR fund will pay for it
mikeh30
29/3/2021
12:03
Hope nobody got impaled on that spike this morning - excellent news but I held off due to mention of the requirement of a P3. They will certainly need to raise more funds for the 2 x trials, I'd guess it'll be between £1-1.50 based on where they raised before, certainly anyone who has held for more than 5 minutes is looking good :)
74tom
29/3/2021
11:36
Nice update from ED: hTTtps://www.equitydevelopment.co.uk/research/the-best-possible-scenario? Our fair value of Destiny Pharma has increased to £213.6m (357p per share) from £156.9m (262p per share) as a result of Destiny becoming a company with two Phase 3-ready programs. NB The Management of Destiny will host an Investor Webinar on the trial results TOMORROW , Tuesday 30th at 3.30pm.
gb904150
29/3/2021
09:07
Agreed. Each to their own. Just add the dips if you believe.
letmepass
29/3/2021
09:00
WOW again, bought at 63p then they doubled now up again. I am holding.
malcolmmm
29/3/2021
09:00
I know that I'm personally not a good enough trader to play the game of selling now and getting in lower. I'd probably mess it up. So easiest for me (and lots of others I imagine) to just hold on and wait, even if it's going to be a long time to revenues or a buyout.
gaiusgracchus
29/3/2021
08:52
Bought weeks ago. It's a great RNS and bodes well for the future but today is a trade day ?
letmepass
29/3/2021
08:50
Welcome LMP. A great buy sign.
babbler
29/3/2021
08:47
Going to be years before it gets to market. Take your profits before the next fundraise
letmepass
29/3/2021
08:14
This is an easy £250m plus company now with two fabulous phase 3 drugs.
supracat
29/3/2021
08:06
Chances of XF-73 making it to market so high now on the back of these 2b results. Market opportunity huge. Market cap a touch over £100m now, seems unlikely to stay that low.
photon
29/3/2021
07:44
The strength of the Phase 2b study data on XF-73 released today was indeed outstanding - the Group now has not one but two Phase 3 ready programs. Equity Dev raises fair value / share to 357p from 262p, see new detailed note here: https://www.equitydevelopment.co.uk/research/the-best-possible-scenario AND DEST CEO & CFO will present to investors at a webinar tomorrow , Tues 30th at 3.30pm. To attend , register here: https://www.equitydevelopment.co.uk/news-and-events/strix-full-year-results-presentation-25th-march-2021-0
edmonda
29/3/2021
07:28
Positive results is an understatement. 99.5% efficacy !! Investors call today at 11am so will get more details thenFantastic figures!
megasonic
29/3/2021
07:27
Outstanding results
t0pgrader
Chat Pages: 21  20  19  18  17  16  15  14  13  12  11  10  Older
ADVFN Advertorial
Your Recent History
LSE
DEST
Destiny Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210412 02:23:35